

Attachment C

Paperwork Reduction Act Submission

OMB # 0938 – 0944

CMS-10142

Summary of MA BPT Changes from CY2024 to CY2025

- Updated Contract Year from CY2024 to CY2025
- Worksheet 3 – MA PROJECTED COST SHARING PMPM
 - Updated Section IV Mapping to include new line 16c dental to coincide with Plan Benefit Package (PBP) updates.

Summary of Part D BPT Changes from CY2024 to CY2025 (Contract Year Updates and Updates Necessary to reflect Inflation Reduction Act)

- Updated Contract Year from CY2024 to CY2025
- Worksheet 1 – Rx BASE PERIOD EXPERIENCE
 - Section II – Added risk score input cells split between LI and NLI (cells I14:I15). Total risk score now a calculated cell.
 - Section III - Adjusted benefit phases consistent with IRA (removal of GAP phase).
 - Section III - Added Manufacturer Discount input cell G38- Grayed out as not applicable until CY2027.
 - Section III – Removed OON cells.
 - Section IV - Added an input within Non-Benefit Expenses for Uncollected Cost Sharing Payments from the Medicare Prescription Payment Plan. Grayed out until CY2027.
 - Added new Section VI for IRA Drug Experience – Includes Insulins, Vaccines, Negotiated Drugs – Negotiated Drugs grayed out for CY2025.
 - Cell M60 - Total Non-LI Brand Discount Amount will be removed for CY2027 as will no longer applicable for a CY2025 base period. Remains in BPT for next two years.
- Worksheet 2 – Rx PROJECTION OF ALLOWED/NON-BENEFIT EXPENSES
 - Section II and Section III - Added rows for Maximum Fair Price Drug projection factors for both utilization and cost. Cells grayed out until CY2026.
 - Section V - Added an input within Non-Benefit Expenses for Uncollected Cost Sharing Payments from the Medicare Prescription Payment Plan.

- Sections V and VII - Moved Gain/Loss and Related Party cells from Worksheet 3 to Worksheet 2.
- Worksheet 3 – Rx CONTRACT PERIOD PROJECTION FOR DEFINED STANDARD COVERAGE
 - Section II – Added risk score input cells split between LI and NLI (cells H12:H13). Total risk score now a calculated cell.
 - Section III - Adjusted benefit phases consistent with IRA (removal of GAP phase). GAP PMPM column also removed.
 - Section III - Added Manufacturer Discount PMPM input cell N31. This is calculated from WS6 Script Projection Inputs.
 - Added Section IV for IRA Drug Experience – Includes Insulins, Vaccines, Negotiated Drugs – Negotiated Drugs grayed out until CY2026.
 - These cells will be calculated from inputs on WS6 Script Projection.
 - Removed old lines 10 and 11 from Section III (Projected % OON).
- Worksheet 4 – Rx Standard Coverage with Actuarially Equivalent Cost Sharing
 - Section IV - Removed “Amounts in Gap” Column.
 - Section IV - Updated several formulas for the changes to script projection worksheet.
 - Section IV - Hard coded 0% cost sharing above catastrophic, as no longer applicable.
 - Section IV - Adjusted net cost of benefit to net out the manufacturer discount entered in script projection worksheet as this is not included in cost sharing in rows above.
 - Section IV - Removed Actuarial Equivalence test for catastrophic cost sharing and coverage in the gap.
 - Section IV – Removed Insulin AE Test, will be handled in PBP.
 - Section V - Adjusted formula for Federal Reinsurance in L20 for IRA change.
- Worksheet 5 – Rx ALTERNATIVE COVERAGE
 - Section IV - Removed Type of Gap coverage and “Gap Amt” column.
 - Section IV - Altered several formulas for the changes to script projection worksheet.
 - Section IV - Adjusted net cost of benefit to net out the manufacturer discount entered in script projection worksheet as this is not included in cost sharing in rows above.
 - Section IV – Removed Alternative Coverage ICL input cell.

- Section IV - Hard coded 0% cost sharing above catastrophic, as no longer applicable.
- Section IV - Adjusted formula for Federal Reinsurance in M51:M52 for IRA change.
- Section VI - Removed Coverage in Gap and Catastrophic Cost Sharing AE tests.
- Section VI – Removed Insulin AE Test, will be handled in PBP.
- Worksheet 6 – Rx Script Projections for Defined Standard, Actuarially Equivalent, or Alternative Coverage
 - Restructured worksheet for changes in benefit phases as a result of the IRA.
 - Moved vaccines and insulins from their own separate section to within each benefit phase.
 - Added manufacturer discount input cells within each phase.
 - Removed Network Pricing inputs.
 - Grayed out cost sharing above catastrophic, as no longer applicable.
 - Added input cells for selected drug subsidy – Grayed out for CY2025.
- Worksheet 7– SUMMARY OF KEY BID ELEMENTS
 - Section II - Adjusted for new benefit phases because of the IRA.
 - Section III - Replaced Prospective Brand Discount Amount with Manufacturer Discount Amount in cell F30.
 - Section III – Added new cell for Maximum Base Beneficiary Premium.
 - This cell is an increase of 6% over CY2024 BPP.
 - BPP entered in line 3 above must be below the Max.

The CY 2025 Draft MA and Part D Bid instructions were updated to reflect the proposed changes presented on the November 2023 User Group Call and to reflect the BPT revisions outlined above.

The revisions were necessary for accuracy and/or applicability and to reflect changes from the Inflation Reduction Act (IRA). The revisions neither increase nor decrease the burden.